GlassScriptPhysician profile
David J Starkey
NPI 1548233844
$3,054.83
in general payments reported to CMS, 2019-2025
29 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $162 · 2021: $31.77 · 2022: $417 · 2023: $436 · 2024: $1,075 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,020.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $490.54 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $395.32 | 2019-2025 | |
| Amgen INC. | $196.68 | 2019-2024 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $170.28 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $95.22 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $84.65 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Insulet Corporation | $63.37 | 2024-2025 | Omnipod |
| Sumitomo Pharma America, INC. | $57.01 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $46.14 | 2022 | |
| Corium, LLC | $39.97 | 2022-2023 | Adlarity |
| Astellas Pharma US INC | $36.01 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $31.46 | 2022 | |
| Merck Sharp & Dohme LLC | $28.59 | 2022-2023 | Januvia, Belsomra, Steglatro |
| Abbott Laboratories | $27.58 | 2022-2023 | Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.20 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $27.07 | 2025 | Intellis Adaptivestim |
| Abiomed | $25.61 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $24.30 | 2025 | Austedo Xr |
| Daiichi Sankyo INC. | $24.22 | 2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $23.59 | 2022 | |
| Dexcom, INC. | $19.80 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $19.38 | 2023 | Gattex |
| Axsome Therapeutics, INC. | $15.80 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.96 | 2024 | Xifaxan |
| Amarin Pharma, INC. | $13.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.05 | 2023 | Xarelto |
| Radius Health, INC. | $12.03 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Starkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.